Skip to main content

Military Health System

DOD participates in new COVID-19 antibody combination prevention trial

Image of Woman gets blood drawn. Miranda Heilweil gets her blood drawn at Madigan Army Medical Center, Washington, one of five DOD sites where the STORM CHASER trial is studying the efficacy of an antibody product that could prevent COVID-19 in people who have been exposed to the virus within eight days. (U.S. Army photo by Janell Cain)

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

While the Military Health System continues to support the development and distribution of COVID-19 vaccines to counter the ongoing public health threat of the disease, it’s investing in other efforts to counter the SARS-CoV-2 virus.

One of those includes evolving therapeutics as part of the U.S. government’s COVID-19 response through clinical trials of a long-acting antibody combination medicine to prevent COVID-19 among people who have been exposed to the disease.

The intramuscular long-acting antibody product, called AZD7442 and developed by AstraZeneca, is undergoing a phase III clinical trial at five Department of Defense sites to study its efficacy among eligible MHS beneficiaries who have recently been exposed to others with SARS-CoV-2 infection.

“This study will run for one year, although interim and primary analyses will likely occur much earlier in 2021,” said Dr. Simon Pollett, associate scientific director and COVID-19 research area director at the Uniformed Services University of the Health Science’s (USU) Infectious Diseases Clinical Research Program (IDCRP).

Under the name STORM CHASER, Pollett’s program is coordinating teams of physicians, nurses, pharmacists, and clinical research staff at Tripler Army Medical Center in Hawaii, Madigan Army Medical Center in Washington, William Beaumont Army Medical Center in Texas, Naval Medical Center Portsmouth in Virginia, and USU in Maryland. The lead investigators at these sites are Army Col. Viseth Ngauy, Army Col. Anjali Kunz, Dr. Gina Kubicz, Navy Lt. Cmdr. Tida Lee, and Army Lt. Col. Jeffrey Livezey, respectively.

This study is designed to prevent the development of illness in people who have been exposed to COVID-19 in care homes and sites with enhanced risk of disease transmission, under the sponsorship of AstraZeneca with support from the U.S. health information technology and clinical research firm IQVIA. IDCRP is supported through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Primarily, STORM CHASER seeks to determine if the antibody injection can prevent COVID-19 in people who were exposed to the SARS-CoV-2 virus – which causes the disease – within the last eight days, but have not yet developed symptoms, explained Pollett. “This may include those exposed by household contacts, in crowded working conditions, in health care settings, and other scenarios,” he added.

A secondary objective of the study is examining whether the antibody injection can reduce viral shedding in those who may develop the disease after receiving the injection, said Pollett. Viral shedding occurs when the virus replicates inside the body and is released to the environment, making the host person contagious to others.

“Reduced viral shedding may perhaps correlate with reduced transmissibility, but this requires further study,” said Pollett.

STORM CHASER also aims to see if individuals who receive the AZD7442 injection after SARS-CoV-2 exposure experience less severe symptoms of COVID-19. Likewise, the clinical trial seeks to explore “sequencing of breakthrough virus to look at antibody escape mutations,” said Navy Capt. Timothy Burgess, IDRCP director. This will help determine whether AZD7442 protects across a range of SARS-CoV-2 strains, including newly emerged variants.

AZD7442 contains infection-fighting proteins called monoclonal antibodies that work to neutralize the virus, thus preventing COVID-19. Each dose is given once as two intramuscular shots in each gluteal region, within eight days of exposure.

If clinical trials are successful and the product receives emergency use authorization from the Food and Drug Administration, this investigational product would become another tool to defeat the COVID-19 pandemic. Two vaccines, by Pfizer-BioNTech and Moderna, are available to the U.S. population older than 16 and 18 years of age, respectively, under FDA’s EUA, with three more vaccines, including AstraZeneca’s, currently in clinical trials.

The vaccines work inside the body by triggering the immune system to make antibodies that will block or kill the SARS-CoV-2 spike protein if it enters the body, which results in immunity to coronavirus. They are given to healthy individuals who have not been exposed to the virus to protect them against getting seriously ill from the disease if they become infected or exposed, and studies are still being conducted to gauge their ability to keep people from spreading the virus.

AZD7442 may provide very rapid protection against COVID-19 in individuals who have been exposed because it is given while the virus is incubating, said Burgess. But those who have already received the COVID-19 vaccine are not eligible to participate in the study.

“The investigational product is intended to provide rapid immunity after exposure, with up to six months of protection thereafter,” said Burgess. “STORM CHASER is examining the efficacy of this.”

If the study is successful in achieving its objective of preventing COVID-19 after exposure, the hope, according to Pollett, is that transmission chains will also be stopped by preventing such COVID-19 cases, but further study is required.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.

If interested in participating in the STORM CHASER trial - please contact Julia Rozman at: julia.rozman.ctr@usuhs.edu.

You also may be interested in...

Genome Sequencing Assists Research at Naval Health Research Center

Article
1/24/2023
Lab technicians doing genome research

Learn how unique samples from naval vessels, US-Mexico border populations, and DOD beneficiaries aided in the Naval Health Research Center’s sequencing efforts.

Recommended Content:

Research & Innovation | Coronavirus & the MHS Response | Coronavirus

U.S. Military HIV Research Lends Lessons Learned to COVID-19

Article
1/19/2023
Gloved hands working in laboratory

The U.S. military has engaged in HIV research for three decades, contributing critical lessons learned, knowledge, and expertise during the COVID-19 research and vaccine development effort.

Recommended Content:

Coronavirus & the MHS Response | DOD HIV/AIDS Prevention Program | Research & Innovation | Coronavirus

Naval Medical Research Center Uses Genome Sequencing for Variants

Article
1/12/2023
Military personnel pose for a group photo

NMRC’s efforts provided important support for sequencing and viral isolation to the Department of Defense and Military Health System.

Recommended Content:

Research & Innovation | Coronavirus & the MHS Response | Coronavirus

USAMRIID Focuses on Genome Sequencing to Detect Variants

Article
1/5/2023
Military medical personnel in laboratory

A connected family of laboratories across the MHS allows a more rapid response to the outbreak.

Recommended Content:

Research & Innovation | Coronavirus & the MHS Response | Coronavirus

Whole Genome Sequencing at Tripler Army Medical Center

Article
12/29/2022
Dr. Keith Fong reviews data with other lab technicians

The third installment in a 6-part series highlighting the efforts of the Military Health System laboratories and the technicians who worked to identify COVID-19 variants using special sequencing technology.

Recommended Content:

Coronavirus & the MHS Response | Research & Innovation | Coronavirus

Walter Reed Army Institute of Research Implements SARS-CoV-2 Genome Sequencing

Article
12/23/2022
Military medical personnel in laboratory

This is the second article in a 6-part series that highlights the work of technicians and scientists in Military Health System laboratories who worked to identify COVID-19 variants using special sequencing technology.

Recommended Content:

Global Health Engagement | Coronavirus & the MHS Response | Research & Innovation

Protect Yourself With Respiratory Illnesses on the Rise

Article Around MHS
12/19/2022
Military medical personnel administering vaccine

"Tis the season, and respiratory illnesses are on the rise. Learn critical health guidance about the viral triple threat of COVID-19, influenza, and the common cold, and the commonsense steps you can take to protect yourself and your family.

Recommended Content:

Coronavirus & the MHS Response | Children's Health | Medical and Dental Preventive Care Fitness | Immunization Tool Kit | Influenza, Northern Hemisphere | Immunization Healthcare Division

Military Labs Use Whole Genome Sequencing of COVID-19 Variants

Article
12/16/2022
Lab technician at work

The first in a 6-part series highlighting the work of technicians and scientists working in support of the MHS who identified COVID-19 variants using special sequencing technology.

Recommended Content:

Research & Innovation | Coronavirus & the MHS Response | Coronavirus

DOD Reduces Health Care Waste by Reusing Crutches

Article
12/15/2022
Military personnel using crutches

When military facilities faced a national shortage of an essential mobility aid, they launched a grassroots initiative that not only ensured patient care, but also created a new waste reduction model within the DHA.

Recommended Content:

Warrior Care | Coronavirus & the MHS Response

Flu Season’s Here: You Still Can Get Your Flu Shot for Protection

Article
12/12/2022
Flu Week Infographic

It’s not too late to get vaccinated against the flu and COVID-19.

Recommended Content:

Immunization Healthcare Division | Immunization Tool Kit | Vaccine Recommendations | COVID-19 Vaccine Efforts | National Immunization Awareness Month 2022 | Immunizations | Winter Safety

Naval Medical Research Center Joint Study with Mount Sinai Uncovers Differences in COVID-19 Immune Response between the Sexes

Article Around MHS
12/5/2022
Amanda Cherry, research assistant, performing diagnostic testing at NMRC

A collaborative study between researchers at Naval Medical Research Center and the Icahn School of Medicine at Mount Sinai, and Princeton University has highlighted immune response differences in the coronavirus infection responses between male and female patients.

Recommended Content:

Medical Research and Development | Coronavirus & the MHS Response | Coronavirus

Get Protected With New COVID-19 Booster and Flu Vaccine

Article Around MHS
10/24/2022
Military medical personnel administering vaccine

There are two vaccines you should consider getting this Fall, and now you can get them both at the same time.

Recommended Content:

Immunizations | COVID-19 Vaccine Efforts | Seasonal Influenza Vaccine Toolkit | Coronavirus and the COVID-19 Vaccine

Collaborating In the ER: Reservists Assist, Learn in Community Hospitals

Article Around MHS
10/20/2022
Military medical personnel in medical training session

In the early days of the COVID-19 pandemic–when there were no vaccines, a shortage of health care workers, and hospitals were beyond capacity– the U.S. health care system needed help. Here's one of many ways the Department of Defense answered the call.

Recommended Content:

Coronavirus & the MHS Response

Time to Get Your Flu Shot and Your COVID-19 Booster, Too

Article
10/14/2022
Senior MHS officials and medics from the Pentagon stand together Oct. 13 after receiving their flu shots and bivalent COVID-19 boosters.."

It's flu shot time. Get your COVID-19 booster at the same time.

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts | Coronavirus and the COVID-19 Vaccine | Seasonal Influenza Vaccine Toolkit | Immunizations | Coronavirus

Prevent the Spread of Influenza and COVID-19 Viruses Within Your Community

Article
10/11/2022
A person getting an injection on their arm.

As families return from summer vacation and students return to school, the influenza (flu) season is approaching while the COVID-19 pandemic is still on-going.

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts | Immunizations | Coronavirus and the COVID-19 Vaccine | Seasonal Influenza Vaccine Toolkit
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 25
Refine your search
Last Updated: December 28, 2022
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery